These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9670613)

  • 1. Diphtheria toxin fusion proteins.
    Foss FM; Saleh MN; Krueger JG; Nichols JC; Murphy JR
    Curr Top Microbiol Immunol; 1998; 234():63-81. PubMed ID: 9670613
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
    Bunn PA
    Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
    [No Abstract]   [Full Text] [Related]  

  • 5. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
    Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
    Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
    [No Abstract]   [Full Text] [Related]  

  • 6. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in the treatment of non-Hodgkin lymphoma: interleukin-2 fusion toxin. A review of selected abstracts from the 2004 Annual Meeting of the American Society of Hematology. December 4-7, 2004, San Diego, California.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 2):1-5; discussion 6-7. PubMed ID: 21434476
    [No Abstract]   [Full Text] [Related]  

  • 8. New advances in the management of cutaneous T-cell lymphoma.
    Young SK
    Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
    Kuzel TM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
    Morgan SJ; Seymour JF; Prince HM; Westerman DA; Wolf MM
    Clin Cancer Res; 2004 May; 10(10):3572-5. PubMed ID: 15161717
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox.
    Vidulich K; Jones D; Duvic M
    Clin Lymphoma Myeloma; 2008 Feb; 8(1):55-8. PubMed ID: 18501089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denileukin diftitox for the treatment of panniculitic lymphoma.
    McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio CC; Rook AH
    Arch Dermatol; 2002 Jun; 138(6):740-2. PubMed ID: 12056952
    [No Abstract]   [Full Text] [Related]  

  • 14. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting diphtheria toxin to growth factor receptors.
    Murphy JR; vanderSpek JC
    Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
    Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
    Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
    Kadin ME; Vonderheid EC
    Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.